Ruben Mesa, MD

Articles

Myelofibrosis: Observation and Triggers to Initiate Therapy

May 19th 2022

Expert Pankit Vachhani, MD, breaks down best practices in observation and dictates when it is best to initiated therapy for myelofibrosis.

Risk Assessment and Staging of Myelofibrosis

May 19th 2022

Experts focus on how best to risk stratify and stage myelofibrosis using appropriate diagnostic tools and workup.

Addressing the Challenges in Diagnosing MF

May 12th 2022

Reflections on the predominant challenges one may face while making a differential diagnosis of myelofibrosis.

Making a Differential Diagnosis of Myelofibrosis

May 12th 2022

Shared insight on the differential diagnosis of myelofibrosis, including advice for identifying primary versus secondary disease.

Polycythemia Vera: Ruxolitinib Use and Goals of Therapy

May 5th 2022

A brief discussion on the role of ruxolitinib in the management of polycythemia vera, followed by a review of goals of therapy in this setting.

Treatment Armamentarium for Polycythemia Vera

May 5th 2022

Pankit Vachhani, MD, provides a comprehensive overview of approved agents used to manage patients with polycythemia vera.

Dr. Mesa on Determinants of Disparities in Cancer Care

May 3rd 2022

Ruben A. Mesa, MD, discusses various determinants of disparities in cancer care.

Making a Differential Diagnosis of Polycythemia Vera

April 28th 2022

Shared insight on making a differential diagnosis of polycythemia vera and properly risk-stratifying patients who present with this disease.

Dr. Mesa on the Importance of Community Engagement for Optimal Care in Oncology

February 10th 2022

Ruben A. Mesa, MD, discusses the importance of community engagement to facilitate optimal care in oncology.

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Mesa on the Unique Characteristics of Pacritinib in Myelofibrosis

June 24th 2021

Ruben A. Mesa, MD, discusses the unique characteristics of pacritinib in the treatment of patients with myelofibrosis.

Dr. Mesa on Data With Momelotinib in Transfusion Independence Responders in Myelofibrosis

June 11th 2021

Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.

Dr. Mesa on the Anticipated Utility of Momelotinib in Myelofibrosis

December 7th 2020

Ruben A. Mesa, MD, discusses the anticipated utility of momelotinib in myelofibrosis.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Mesa on Emerging Therapies in Myelofibrosis

September 23rd 2020

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Dr. Mesa on Mitigating Racial Disparities in MPN Clinical Trials

August 5th 2020

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

April 21st 2020

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Dr. Mesa on Unanswered Questions Regarding JAK Inhibitors in Myelofibrosis

April 11th 2020

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Dr. Mesa on Challenges in Myelofibrosis Treatment

April 8th 2020

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.

Dr. Mesa on Investigative Therapies in Myelofibrosis

March 26th 2020

Ruben Mesa, MD, discusses therapiesunder investigation in myelofibrosis.